特应性皮炎患者外用糖皮质激素恐惧的系统综述
该系统综述检索1946年至2016年的文献,纳入16项横断面研究,评估特应性皮炎患者及其照护者外用糖皮质激素恐惧的命名、患病率、来源及对治疗依从性的影响。恐惧患病率从21.0%到83.7%不等,定义和评估方法差异大;两项比较研究显示恐惧组不依从率显著更高。恐惧特征跨文化常见,可能与非依从相关,但缺乏标准化阻碍数据比较。
要点
- 外用糖皮质激素恐惧在特应性皮炎患者中常见,患病率21.0%至83.7%。
- 恐惧组患者治疗不依从率显著高于非恐惧组。
- 恐惧定义和评估方法缺乏标准化,限制数据比较。
核心结论
- 外用糖皮质激素恐惧的特征跨文化常见,可能与更高的不依从率相关。
- 恐惧患者及信息来源可作为提高治疗依从性的干预靶点。
- 恐惧的命名和评估方法缺乏标准化,阻碍定量比较和数据外推。
研究设计与样本
- 纳入评估特应性皮炎患者或其照护者外用糖皮质激素恐惧的文章,共16项符合标准,均为横断面研究。
- 研究质量采用改良版牛津循证医学中心质量评级方案评估。
主要发现
- 外用糖皮质激素恐惧患病率范围为21.0%(95% CI,15.8%-26.2%)至83.7%(95% CI,81.9%-85.5%)。
- 恐惧定义从担忧到非理性恐惧不等,评估问卷问题数1至69个。
- 两项比较恐惧组与非恐惧组不依从性的研究中,恐惧组不依从率显著更高(49.4% vs 14.1%和29.3% vs 9.8%)。
- 患者获取糖皮质激素信息的来源包括医生、朋友和亲属、广播媒体、印刷媒体和互联网。
临床怎么用
- 临床应识别特应性皮炎患者及其照护者的外用糖皮质激素恐惧,以针对性干预提高依从性。
- 关注患者获取糖皮质激素信息的来源,纠正误解。
局限性
- 所有纳入研究均为横断面设计。
- 恐惧的命名和评估方法缺乏标准化,阻碍定量比较和数据外推。
- 需要标准化定义和评估方法的进一步研究来表征该现象并评估干预效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Topical corticosteroid (TCS) phobia refers to the negative feelings and beliefs related to TCSs experienced by patients and patients' caregivers. This phenomenon may be a major contributing factor in treatment failure in patients with atopic dermatitis, yet it has been sparsely described in the literature. OBJECTIVE: To systematically assess the nomenclature, prevalence, origins, and effect on treatment adherence of TCS phobia in atopic dermatitis. EVIDENCE REVIEW: A literature search was conducted using specific eligibility criteria across electronic databases, including Ovid (MEDLINE, EMBASE), PubMed, and Web of Science, for articles published from January 1, 1946, to October 31, 2016. Included articles must have assessed TCS phobia in patients with atopic dermatitis or their caregivers. Quality ratings of studies were based on a modified version of the Oxford Centre for Evidence-Based Medicine quality rating scheme for individual studies. FINDINGS: Of the 490 articles identified by literature search, 16 met the eligibility criteria. All studies were cross-sectional. Topical corticosteroid phobia prevalence ranged from 21.0% (95% CI, 15.8%-26.2%) to 83.7% (95% CI, 81.9%-85.5%). There was significant variation in how phobia was defined, ranging from concern to irrational fear. Questionnaires used to assess for TCS phobia included 1 to 69 questions. In the 2 studies that compared nonadherence between a phobia group and a nonphobia group, patients in both phobia groups were found to have a significantly higher rate of nonadherence (49.4% vs 14.1% and 29.3% vs 9.8%). The sources from which patients were receiving information about corticosteroids included physicians, friends and relatives, broadcast media, print media, and the internet. CONCLUSIONS AND RELEVANCE: Features of TCS phobia are commonly reported by patients across cultures and may be associated with a higher rate of nonadherence. Patients with TCS phobia and the sources from which patients are receiving information about corticosteroids may be targetable for intervention to increase adherence to treatment regimens. The nomenclature and assessment methods for TCS phobia used in studies, however, lack standardization, precluding quantitative comparison and extrapolation of data. Additional research, using standardized definitions and methods of assessment, is needed to better characterize this phenomenon and evaluate the efficacy of potential interventions.
引用
- Li AW, Yin ES, Antaya RJ, et al. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. JAMA Dermatol. 2017. PMID: 28724128. doi:10.1001/jamadermatol.2017.2437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。